E
Athira Pharma, Inc. ATHA
$0.2843 -$0.0197-6.48% NASDAQ
Recommendation
Prev Close
$0.2843
Volume
173,982
Avg Vol (90D)
225,809
Market Cap
$11.10M
Dividend & Yield
--
52-Week Range
$0.2195 - $3.67
P/E (TTM)
--
EPS (TTM)
-$2.52
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Athira Pharma's 2024 Financial Results and Pipeline Progress
3/1/2025 - TipRanks Financial Blog
Athira Pharma (NASDAQ:ATHA) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS
2/27/2025 - Ticker Report
Athira Pharma Inc Reports Annual EPS of -$2.52, Narrowing Losses and Reducing Expenses in 2024
2/27/2025 - GuruFocus
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
2/27/2025 - GuruFocus
Athira Pharma announces exploration of strategic alternatives
2/27/2025 - The Fly
Athira Pharma reports FY24 EPS ($2.52) vs. ($3.09) last year
2/27/2025 - The Fly
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
2/27/2025 - Globe Newswire
Critical Survey: Athira Pharma (NASDAQ:ATHA) and Molecular Partners (NASDAQ:MOLN)
2/18/2025 - Ticker Report
Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 30.7% in January
2/16/2025 - Ticker Report
Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m
1/17/2025 - Simply Wall St
Bothell's Athira Pharma to pay $4M to settle falsified research claims
1/8/2025 - BizJournals.com - Nat'l Business News
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
1/7/2025 - GeekWire
Athira Pharma to pay $4M to settle False Claims Act allegations
1/7/2025 - The Fly
Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares of Stock
1/4/2025 - Ticker Report
Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares
1/4/2025 - MarketBeat
Grasping for hope: The heartbreaking journey through Alzheimer's drug trials
12/14/2024 - The Mercury News: Health
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in ...
12/6/2024 - GuruFocus
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in ...
12/6/2024 - GuruFocus
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
12/6/2024 - Globe Newswire
Athira Pharma's Regulatory Compliance Challenges Threaten Drug Development Pipeline
11/9/2024 - TipRanks Financial Blog
Athira Pharma reports Q3 EPS (75c), consensus (71c)
11/7/2024 - The Fly
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
11/7/2024 - Globe Newswire
3 Penny Stocks to Watch Now, 11/5/24
11/5/2024 - TipRanks Financial Blog
Perceptive Advisors LLC Acquires Significant Stake in Athira Pharma Inc
11/1/2024 - GuruFocus
Athira Pharma to present results from Phase 2/3 LIFT-AD trial
10/22/2024 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$95.81M
EBIT (TTM)
-$96.78M
Net Income (TTM)
-$96.94M
Balance Sheet
Total Assets (Q)
$58.78M
Total Debt (Q)
$1.22M
Total Liabilities (Q)
$13.94M
Book Value Per Share (Q)
$1.15
Cash Flow
Cash from Operations (TTM)
-$97.17M
Cash from Investing (TTM)
$54.83M
Cash from Financing (TTM)
$194.00K
Net Change in Cash (TTM)
-$42.15M
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.62
7-Day Total Return
24.15%
30-Day Total Return
-15.21%
60-Day Total Return
-46.76%
90-Day Total Return
-51.39%
Year to Date Total Return
-48.32%
1-Year Total Return
-85.19%
2-Year Total Return
-89.66%
3-Year Total Return
-97.42%
5-Year Total Return
--
52-week Low
Apr 08, 2025 - $0.2195
52-week High
Aug 19, 2024 - $3.67
Valuation
Market Cap
$11.10M - Nano Cap
Enterprise Value
-$38.96M
Price/Sales (TTM)
--
Price/Book (Q)
0.25
Dividends and Shares
Shares Outstanding
38.70M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.athira.com
Phone Number
425 620 8501
Address
18706 North Creek Parkway
Bothell, WA 98011
Country
United States
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed